膜性肾病中PLA2R1抗体结构域特异性水平的临床相关性
该前瞻性队列纳入150例新诊断PLA2R1相关膜性肾病(MN)患者,用Western blot和ELISA分析表位识别模式及结构域特异性PLA2R1抗体水平。研究识别出CTLD8结构域的第四个表位区域,24例(16.0%)患者可识别该区域;所有患者基线时抗体同时结合N端(CysR-FnII-CTLD1)和C端(CTLD7-CTLD8)区域。133例(89%)患者蛋白尿缓解,且与结构域识别谱无关;结构域特异性抗体水平与总抗体水平相关,但不能独立于总抗体水平预测疾病结局。
要点
- 新诊断PLA2R1相关MN患者均至少识别PLA2R1的N端和C端两个表位区域。
- 识别出CTLD8的第四个表位区域,见于24例(16.0%)患者。
- 总抗PLA2R1抗体水平而非表位识别谱与临床结局相关。
核心结论
- 所有PLA2R1相关MN患者在诊断时至少识别PLA2R1的N端和C端两个表位区域,不支持「表位扩展」决定预后的假说。
- 总抗PLA2R1抗体水平而非诊断时的表位识别谱与患者临床结局相关。
研究设计与样本
- 前瞻性队列研究,纳入150例新诊断PLA2R1相关膜性肾病患者。
- 采用Western blot和ELISA检测表位识别模式及结构域特异性PLA2R1抗体水平。
主要发现
- 识别出PLA2R1的CTLD8结构域第四个表位区域,24例(16.0%)患者可识别。
- 所有患者基线时抗PLA2R1抗体同时结合N端(CysR-FnII-CTLD1)和C端(CTLD7-CTLD8)区域。
- 133例(89%)患者蛋白尿缓解,且不依赖于结构域识别谱。
- 靶向CysR、CTLD1和CTLD7的结构域特异性抗体水平与总抗体水平相关(Spearman's rho分别为0.95、0.64、0.40;P<0.001、P<0.001、P=0.002)。
- 结构域特异性抗体水平不能独立于总抗PLA2R1抗体水平预测疾病结局。
临床怎么用
- 临床评估PLA2R1相关MN预后时应关注总抗PLA2R1抗体水平,而非表位识别谱。
- 结构域特异性抗体检测目前不推荐用于独立预测疾病结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibodies against phospholipase A2 receptor 1 (PLA2R1) are found in 80% of patients with membranous nephropathy, and previous studies described three autoantibody-targeted PLA2R1 epitope regions. Although anti-PLA2R1 antibody levels are closely associated with treatment response and disease prognosis, the clinical role of epitope regions targeted by autoantibodies is unclear. METHODS: In a prospective cohort of 150 patients with newly diagnosed PLA2R1-associated membranous nephropathy, we investigated the clinical role of epitope-recognition patterns and domain-specific PLA2R1 antibody levels by western blot and ELISA. RESULTS: We identified a fourth epitope region in the CTLD8 domain of PLA2R1, which was recognized by anti-PLA2R1 antibodies in 24 (16.0%) patients. In all study patients, anti-PLA2R1 antibodies bound both the N-terminal (CysR-FnII-CTLD1) region and the C-terminal (CTLD7-CTLD8) region of PLA2R1 at study enrollment. The total anti-PLA2R1 antibody levels of patients determined detection of domain-specific PLA2R1 antibodies, and thereby epitope-recognition patterns. A remission of proteinuria occurred in 133 (89%) patients and was not dependent on the domain-recognition profiles. A newly developed ELISA showed that domain-specific PLA2R1 antibody levels targeting CysR, CTLD1, and CTLD7 strongly correlate with the total anti-PLA2R1 antibody level (Spearman's rho, 0.95, 0.64, and 0.40; P<0.001, P<0.001, and P=0.002, respectively) but do not predict disease outcome independently of total anti-PLA2R1 antibody levels. CONCLUSIONS: All patients with PLA2R1-associated membranous nephropathy recognize at least two epitope regions in the N- and C-terminals of PLA2R1 at diagnosis, contradicting the hypothesis that PLA2R1 "epitope spreading" determines the prognosis of membranous nephropathy. Total anti-PLA2R1 antibody levels, but not the epitope-recognition profiles at the time of diagnosis, are relevant for the clinical outcome of patients with this disease.
引用
- Reinhard L, Zahner G, Menzel S, et al. Clinical Relevance of Domain-Specific Phospholipase A2 Receptor 1 Antibody Levels in Patients with Membranous Nephropathy. J Am Soc Nephrol. 2019. PMID: 31843985. doi:10.1681/ASN.2019030273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。